Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial

Thermo Fisher has entered a strategic collaboration agreement with Arcturus for the Phase III development of ARCT-032 to treat cystic fibrosis. Thermo Fisher will provide integrated manufacturing, clinical research and commercial readiness services. If ARCT-032 shows positive Phase II results, Arcturus plans a Phase III clinical programme with Thermo Fisher’s PPD research business. Credit: THICHA SATAPITANON/Shutterstock.com. Thermo Fisher Scientific has entered into a strategic collaboration agreement with Arcturus Therapeutics for the Phase III development of ARCT-032 to treat cystic fibrosis. The collaboration will also focus on the potential commercialisation of ARCT-032, Arcturus’ investigational messenger RNA (mRNA) therapy. LOA and PTSR…

Source: Clinical Trials Arena